Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas

NCT00589875 is registered in ClinicalTrials.gov with Candel Therapeutics, Inc. as lead sponsor.

NCT NCT00589875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00589875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Lead sponsor
Candel Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2016
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme, high grade glioma, malignant glioma